Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: Study using a Fischer 344 rat substrain deficient in its enzyme activity

Japanese Journal of Pharmacology

Volumn 88, Issue 4, 2002, Pages 442-450

  Mitani, Hironobu ^a   Takimoto, Misato ^a   Hughes, Thomas E ^a   Kimura, Masaaki ^a  

^a NOVARTIS PHARMA K K   (Japan)

Author keywords

Diabetes; Dipeptidyl peptidase IV; Fischer 344 rat; Glucose tolerance; High fat diet

Indexed keywords

1 [2 [(5 CYANOPYRIDIN 2 YL)AMINO]ETHYLAMINO]ACETYL 2 CYANOPYRROLIDINE; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; GLUCOSE; INSULIN; LIPID; PHOSPHOLIPID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; NITRILE; NVP-DPP728; PROTEINASE INHIBITOR; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEEDING; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIPID DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PLASMA; RAT; RAT STRAIN; STANDARD; STIMULATION; ANIMAL; BLOOD; ENZYMOLOGY; FAT INTAKE; FISCHER 344 RAT; GLUCOSE TOLERANCE TEST; METABOLISM; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; DIETARY FATS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INSULIN; LIPIDS; NITRILES; PROTEASE INHIBITORS; PYRROLIDINES; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TIME FACTORS;

EID: 0035985294     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.88.442     Document Type: Article

References (34)

1. Glucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes
2. Glucagon-like peptides
3. Is glucagon-like peptide 1 an incretin hormone?
4. Anti-diabetogenic effect of glucagon-like peptide-1 (7 - 36) amide in normal subjects and patients with diabetes mellitus
5. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7 - 36) amide in type 2 (non-insulin-dependent) diabetic patients
6. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM
7. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7 - 36 amide]) in patients with NIDDM
8. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide I receptor gene
9. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
10. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig
11. Dipeptidyl-peptidase IV hydrolyzes gastric inhibitory polypeptide, glucagon-like peptide-1(7 - 36)amide, peptide histidine methionine and is responsible for their degradation in human serum
12. Glucagon-like peptide-1-(9 - 36) amide is a major metabolite of glucagon-like peptide-1-(7 - 36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor
13. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig
14. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide
15. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7 - 36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
16. Perspectives in diabetes: Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
17. On the treatment of diabetes mellitus with glucagon-like peptide-1
18. Deficiency of membrane-bound dipeptidyl aminopeptidase IV in a certain rat strain
19. A Fischer rat substrain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein. Use as a liver-cell transplantation model
20. Biosynthesis and degradation of altered immature forms of intestinal dipeptidyl peptidase IV in a rat strain lacking the enzyme
21. Is CD26/dipeptidyl peptidase IV a really important molecule in T cell activation of a certain rat strain?
22. Studies of liver repopulation using the dipeptidyl peptidase IV-deficient rat and other rodent recipients: Cell size and structure relationships regulate capacity for increased transplanted hepatocyte mass in the liver lobule
23. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV
24. The structure and function of CD26 in the T-cell immune response
25. NVP-DPP728 (1-[2-[(5-cyanopyridin-2-yl)amino]ethyl-amino]acetyl-2-cyano-(S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV
26. Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV?
27. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits
28. Increased activity of vascular ACE related to atherosclerotic lesions in hyperlipidemic rabbits
29. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
30. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs
31. The enteroinsular axis in dipeptidyl peptidase IV-negative rats
32. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats
33. NVP-DPP728, a novel, orally active dipeptidyl peptidase IV (DPP-IV) inhibitor, prevents glucagon-like peptide-1 (GLP-1) inactivation in rats
34. Dipeptidyl-peptidase IV (CD26) - Role in the inactivation of regulatory peptides